SG11201406032TA - Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcoma - Google Patents
Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcomaInfo
- Publication number
- SG11201406032TA SG11201406032TA SG11201406032TA SG11201406032TA SG11201406032TA SG 11201406032T A SG11201406032T A SG 11201406032TA SG 11201406032T A SG11201406032T A SG 11201406032TA SG 11201406032T A SG11201406032T A SG 11201406032TA SG 11201406032T A SG11201406032T A SG 11201406032TA
- Authority
- SG
- Singapore
- Prior art keywords
- chondrosarcoma
- occuring
- prophylactic
- bone
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012070351 | 2012-03-26 | ||
JP2012235784 | 2012-10-25 | ||
PCT/JP2013/057706 WO2013146435A1 (en) | 2012-03-26 | 2013-03-18 | Agent for preventing or treating giant cell tumor or chondrosarcoma arising in bone/soft tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201406032TA true SG11201406032TA (en) | 2014-11-27 |
Family
ID=49259696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406032TA SG11201406032TA (en) | 2012-03-26 | 2013-03-18 | Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcoma |
Country Status (11)
Country | Link |
---|---|
US (1) | US10660882B2 (en) |
EP (1) | EP2832367B1 (en) |
JP (2) | JP5865995B2 (en) |
KR (1) | KR102199273B1 (en) |
CN (2) | CN104302322A (en) |
AU (1) | AU2013238126C1 (en) |
CA (1) | CA2868311C (en) |
HK (1) | HK1203818A1 (en) |
NZ (1) | NZ700872A (en) |
SG (1) | SG11201406032TA (en) |
WO (1) | WO2013146435A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10660882B2 (en) | 2012-03-26 | 2020-05-26 | Nippon Chemiphar Co., Ltd. | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma |
WO2015046388A1 (en) * | 2013-09-25 | 2015-04-02 | 日本ケミファ株式会社 | Drug for preventing, treating or preventing metastasis of giant cell tumor that occurs in bone or soft parts, chondrosarcoma, or osteosarcoma, local injection for arterial embolization, and artificial bone |
CN103599093B (en) * | 2013-11-18 | 2016-06-01 | 中国医学科学院生物医学工程研究所 | A kind of anti-HPV pharmaceutical preparation and purposes |
CA2969341C (en) * | 2014-12-22 | 2023-07-04 | Five Prime Therapeutics, Inc. | Anti-csf1r antibodies for treating pvns |
JP6703824B2 (en) * | 2015-11-30 | 2020-06-03 | シスメックス株式会社 | Cell selection method, cell detection method, cell selection device, and cell detection device |
AU2016363691A1 (en) * | 2015-12-01 | 2018-06-21 | Theriac Biomedicale Inc. | PPAR-gamma activators and their therapeutical usages |
KR102650228B1 (en) | 2021-10-06 | 2024-03-21 | 단국대학교 천안캠퍼스 산학협력단 | Ion-supported bioactive glass nanoparticle and preparation method thereof |
CN116875550B (en) * | 2023-09-08 | 2023-12-26 | 天津市肿瘤医院(天津医科大学肿瘤医院) | FABP4 + C1q + Macrophage and its preparation method and use |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06192084A (en) | 1992-06-30 | 1994-07-12 | Kaken Pharmaceut Co Ltd | Inhibitor of cancer metastasis |
US5753702A (en) | 1996-05-22 | 1998-05-19 | University Of Vermont | Arachidonic acid metabolite, 16-hete |
US7101875B2 (en) * | 2001-12-03 | 2006-09-05 | Wyeth | Methods for treating arthritic disorders |
US6635771B2 (en) | 2001-12-03 | 2003-10-21 | Wyeth | N-benzhydryl indole compounds |
US6984735B2 (en) | 2001-12-03 | 2006-01-10 | Wyeth | Process for making an aldehyde |
US7605156B2 (en) | 2001-12-03 | 2009-10-20 | Wyeth | Methods for the use of inhibitors of cytosolic phospholipase A2 |
US7713964B2 (en) | 2001-12-03 | 2010-05-11 | Wyeth Llc | Methods for treating asthmatic conditions |
US6797708B2 (en) | 2001-12-03 | 2004-09-28 | Wyeth | Inhibitors of cytosolic phospholipase A2 |
US20030220374A1 (en) | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
DE10237571A1 (en) | 2002-08-13 | 2004-02-26 | Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin | Endovascular implant with active coating |
US20060240014A1 (en) | 2003-06-03 | 2006-10-26 | Beth Israel Deaconess Medical Center | Methods and compounds for the treatment of vascular stenosis |
JP2007015930A (en) | 2004-09-13 | 2007-01-25 | Ono Pharmaceut Co Ltd | Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same |
JP2005200419A (en) | 2004-01-16 | 2005-07-28 | National Health Research Inst | Method for treating cancer |
JPWO2005103012A1 (en) | 2004-04-21 | 2008-03-13 | 小野薬品工業株式会社 | Hydrazinoheterocyclic nitrile compounds and uses thereof |
JP4179219B2 (en) | 2004-05-14 | 2008-11-12 | 松下電器産業株式会社 | Electric water heater |
JP2005343802A (en) | 2004-05-31 | 2005-12-15 | Norifumi Sakayama | Method for suppressing proliferation of cancer cell by using non-steroidal antiinflammatory analgesic agent for external use |
US7250550B2 (en) | 2004-10-22 | 2007-07-31 | Wright Medical Technology, Inc. | Synthetic bone substitute material |
KR100753480B1 (en) * | 2006-01-27 | 2007-08-31 | 씨제이 주식회사 | Zaltoprofen-containing sustained release tablet and process for the preparation thereof |
TW200815429A (en) | 2006-04-11 | 2008-04-01 | Smithkline Beecham Corp | Thiazolidinedione derivatives as PI3 kinase inhibitors |
WO2008026729A1 (en) | 2006-09-01 | 2008-03-06 | National University Corporation Chiba University | Therapeutic agent for pigmented villonodular synovitis or giant cell tumor of tendon sheath or bone |
MX2009009520A (en) | 2007-03-07 | 2009-11-18 | Janssen Pharmaceutica Nv | Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators. |
MX2009009519A (en) | 2007-03-07 | 2009-11-18 | Janssen Pharmaceutica Nv | Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators. |
CN101679322A (en) | 2007-03-07 | 2010-03-24 | 詹森药业有限公司 | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
JP6324653B2 (en) | 2008-04-15 | 2018-05-16 | ライフ サイエンス エンタープライジズ インコーポレイテッド | Minimally invasive treatment of vertebrae using bone cement containing bone cement (MITV) |
AU2009264777B2 (en) | 2008-07-02 | 2012-02-23 | Next21 K.K. | Artificial bone material having controlled calcium ion elution |
WO2011073788A2 (en) | 2009-12-18 | 2011-06-23 | Dr Reddy's Laboratories, Limited | Balaglitazone compositions and methods |
JP2013519730A (en) | 2010-02-17 | 2013-05-30 | ヤンセン ファーマシューティカ エヌ.ベー. | Aminothiazolones as estrogen-related receptor alpha modulators |
JP2013519729A (en) | 2010-02-17 | 2013-05-30 | ヤンセン ファーマシューティカ エヌ.ベー. | Aminothiazolones as estrogen-related receptor alpha modulators |
WO2011149841A1 (en) | 2010-05-25 | 2011-12-01 | Janssen Pharmaceutica Nv | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS |
US10660882B2 (en) | 2012-03-26 | 2020-05-26 | Nippon Chemiphar Co., Ltd. | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma |
WO2015046388A1 (en) | 2013-09-25 | 2015-04-02 | 日本ケミファ株式会社 | Drug for preventing, treating or preventing metastasis of giant cell tumor that occurs in bone or soft parts, chondrosarcoma, or osteosarcoma, local injection for arterial embolization, and artificial bone |
US9907882B2 (en) | 2014-04-18 | 2018-03-06 | Warsaw Orthopedic, Inc. | Demineralized bone matrix with improved osteoinductivity |
-
2013
- 2013-03-18 US US14/387,981 patent/US10660882B2/en active Active
- 2013-03-18 CN CN201380016296.XA patent/CN104302322A/en active Pending
- 2013-03-18 EP EP13769796.7A patent/EP2832367B1/en active Active
- 2013-03-18 CN CN201610647601.0A patent/CN106267210A/en active Pending
- 2013-03-18 SG SG11201406032TA patent/SG11201406032TA/en unknown
- 2013-03-18 KR KR1020147029881A patent/KR102199273B1/en active IP Right Grant
- 2013-03-18 WO PCT/JP2013/057706 patent/WO2013146435A1/en active Application Filing
- 2013-03-18 CA CA2868311A patent/CA2868311C/en active Active
- 2013-03-18 AU AU2013238126A patent/AU2013238126C1/en not_active Ceased
- 2013-03-18 NZ NZ700872A patent/NZ700872A/en not_active IP Right Cessation
- 2013-03-18 JP JP2014507736A patent/JP5865995B2/en active Active
-
2015
- 2015-05-06 HK HK15104298.4A patent/HK1203818A1/en unknown
- 2015-12-25 JP JP2015252893A patent/JP6205403B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPWO2013146435A1 (en) | 2015-12-10 |
EP2832367A1 (en) | 2015-02-04 |
KR20140139070A (en) | 2014-12-04 |
AU2013238126A1 (en) | 2014-11-06 |
CA2868311A1 (en) | 2013-10-03 |
CN104302322A (en) | 2015-01-21 |
NZ700872A (en) | 2016-09-30 |
KR102199273B1 (en) | 2021-01-06 |
JP2016102129A (en) | 2016-06-02 |
AU2013238126B2 (en) | 2017-12-21 |
JP5865995B2 (en) | 2016-02-17 |
EP2832367A4 (en) | 2015-12-16 |
AU2013238126C1 (en) | 2018-06-14 |
WO2013146435A1 (en) | 2013-10-03 |
CN106267210A (en) | 2017-01-04 |
JP6205403B2 (en) | 2017-09-27 |
HK1203818A1 (en) | 2015-11-06 |
EP2832367B1 (en) | 2020-07-15 |
US20150045396A1 (en) | 2015-02-12 |
CA2868311C (en) | 2021-06-22 |
US10660882B2 (en) | 2020-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201406032TA (en) | Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcoma | |
PT2771041T (en) | Compositions and their use in bone healing | |
EP2701621A4 (en) | Methods and instruments for use in vertebral treatment | |
EP2897625A4 (en) | Amniotic membrane and its use in wound healing and tissue engineering constructs | |
DK2608777T3 (en) | Compositions and Methods for Cardiac Therapy | |
EP2608746A4 (en) | Implants, surgical methods, and instrumentation for use in femoroacetabular impingement surgeries | |
EP2633873A4 (en) | Drug injecting apparatus for use in skin surgery | |
HK1198625A1 (en) | Implants and methods of using the implants to fill holes in bone tissue | |
EP2563426A4 (en) | High shear application in medical therapy | |
ZA201303810B (en) | Methods and compositions suitable for promoting healthy skin | |
GB201012336D0 (en) | Surgical device and procedure | |
EP2544655A4 (en) | Compositions and methods for treating skin | |
HK1187345A1 (en) | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | |
HK1203338A1 (en) | Methods and devices for soft tissue dissection | |
ZA201504815B (en) | Valve assemblies for expandable implants and tissue expanders | |
IL236399B1 (en) | Selectively polymerizable compositions and methods of use in vivo | |
HK1206987A1 (en) | Prophylactic and or therapeutic agent for radiation damage | |
IL222479A0 (en) | Devices and methods for tissue engineering | |
EP2837319A4 (en) | In vivo introduction device, and endoscope having in vivo introduction device | |
GB201217230D0 (en) | Yarashi bone and plate holding forceps | |
IL238951B (en) | Valve assemblies for implantable prostheses and tissue expanders | |
EP2564849A4 (en) | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs | |
HK1203159A1 (en) | Prophylactic agent and or therapeutic agent for stress urinary incontinence | |
EP2903559A4 (en) | Conductive and degradable implant for pelvic tissue treatment | |
HUE037564T2 (en) | Vaginal tissue rejuvenation compositions and methods |